Replies to post #196831 on Biotech Values

[north40000]

AGN will have competition there from Amarin's Vascepa, IMO. I will wager Vascepa is less expensive too...works for me.

[DewDiligence]

(AGN)—Auven Therapeutics (private) reports phase-2b/3 data in dry-eye disease:

http://finance.yahoo.com/news/auven-therapeutics-announces-positive-results-123000810.html

Auven’s drug candidate, Seciera, is a proprietary formulation of cyclosporine, which is the active ingredient in AGN’s second-biggest-selling drug, Restasis.